Compare ZTO & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZTO | UTHR |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 20.3B |
| IPO Year | 2016 | 1999 |
| Metric | ZTO | UTHR |
|---|---|---|
| Price | $21.68 | $489.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $21.90 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 1.5M | 424.3K |
| Earning Date | 11-19-2025 | 10-29-2025 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | N/A | ★ 16.08 |
| EPS | 1.16 | ★ 26.38 |
| Revenue | ★ $6,673,175,085.00 | $3,128,400,000.00 |
| Revenue This Year | $12.15 | $13.64 |
| Revenue Next Year | $11.36 | $5.78 |
| P/E Ratio | $18.69 | ★ $18.55 |
| Revenue Growth | 13.17 | ★ 13.50 |
| 52 Week Low | $16.34 | $266.98 |
| 52 Week High | $22.01 | $492.62 |
| Indicator | ZTO | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 77.13 | 68.10 |
| Support Level | $20.31 | $470.13 |
| Resistance Level | $20.90 | $492.62 |
| Average True Range (ATR) | 0.42 | 10.72 |
| MACD | 0.19 | -0.53 |
| Stochastic Oscillator | 93.69 | 89.55 |
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 19.4% in 2024. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 78% voting rights as of March 31, 2025. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 8.9% interest.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.